Application of pumpkin protein in preparing medicament for treating chronic myeloid leukemia

A technology for chronic myeloid and leukemia, which is applied in the application field of pumpkin protein in the preparation of drugs for the treatment of chronic myeloid leukemia, and can solve problems such as toxicity and limited application.

Inactive Publication Date: 2009-08-05
FUJIAN MEDICAL UNIV +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Because the B chain of type 2 RIP has the function of lectin and can recognize D-galactose on th

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pumpkin protein in preparing medicament for treating chronic myeloid leukemia
  • Application of pumpkin protein in preparing medicament for treating chronic myeloid leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0009] Example 1: Inhibitory effect of pumpkin protein combined with STI571 on K562 cells

[0010] Method: The K562 cells in the logarithmic growth phase were inoculated on a 96-well culture plate, and the inoculation amount per well was 6×10 3 / 120 μL. Experimental components CUS group (2 and 4 mg / L), STI571 group (0.05, 0.1, 0.2 and 0.4 μmol / L) and CUS+STI571 group (combination of CUS and STI571 at different concentrations above), add 20 μL to each well, set 4 duplicate wells; each well of the negative control group was added with the same amount of solvent, and 8 duplicate wells were set up, and 140 μL of nutrient solution was added to the blank control wells for zero adjustment of the instrument. Set 5% CO 2 , Incubate at 37°C for 72 hours, add 10 μL of 5 mg / mL MTT to each well, continue to incubate for 4 hours, add 140 μL of lysate (10% SDS, 5% isobutanol, adjusted to pH 4.5 with HCL) to each well, and place at 37°C for 24 hours , Measure the absorbance of each well wi...

Embodiment 2

[0015] Example 2: Effect of Pumpkin Protein Combined with STI571 Inducing K562 Cell Apoptosis

[0016] Methods: About 10 K562 cells treated with CUS (2 and 4 mg / L), STI571 (0.1 and 0.2 μmol / L) and CUS+STI571 (the combination of CUS and STI571 at different concentrations above) were collected for 72 hours, respectively. 6 , after washing with PBS, add pre-cooled (4°C) 70% ethanol, fix at -20°C for more than 12 hours, centrifuge to remove ethanol, wash with PBS twice and resuspend, with PI solution (containing 0.005% PI, 0.1% TritonX- 100, 0.1mmol·L -1 EDTA and 0.01% RNase A) Stained at room temperature in the dark for 30 minutes, and the percentage of apoptotic cells was measured by flow cytometry. Refer to the literature (Jin Zhengjun. Addition in combined drug use. Chinese Journal of Pharmacology, 1980; 1(2): 70-76) to calculate the q value and judge the effect of combined drug use: q=E a+b / (E a +E b -E a ×E b ), where E a+b is the percentage of apoptotic cells when ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Apoptosis rateaaaaaaaaaa
Login to view more

Abstract

The invention discloses application of pumpkin proteins in preparing a medicine for treating chronic myelocytic leukemia. When the pumpkin proteins and a BCR-ABL tyrosine kinase inhibitor are combined, the functions of inhibiting the proliferation and inducing the apoptosis of chronic myelocytic leukemia cells are obviously enhanced, and the pumpkin proteins and the BCR-ABL tyrosine kinase inhibitor have synergism. Therefore, the pumpkin proteins can be combined with the tyrosine kinase inhibitor in treating chronic myelocytic leukemia.

Description

technical field [0001] The invention relates to the application of pumpkin protein in the preparation of medicines for treating chronic myeloid leukemia, in particular to the application of combined application of pumpkin protein and tyrosine kinase inhibitor to treat chronic myeloid leukemia. Background technique [0002] Chronic myelogenous leukemia (CML) is a malignant clonal proliferative disease of hematopoietic stem cells, the incidence of which accounts for 15% to 20% of adult leukemia. 95% of CML patients have a characteristic Ph chromosome, that is, the abl proto-oncogene on chromosome 9 is transferred to the bcr breakage region of chromosome 22, forming a bcr-abl fusion gene, and the BCR-ABL protein encoded by it has a strong tyrosine Acid kinase activity can stimulate the abnormal proliferation of granulocytes and inhibit their apoptosis by interfering with normal cell signal transduction, which is the molecular basis of the pathogenesis of CML. Therefore, target...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/42A61K38/02A61K45/06A61P35/02A61K31/506
Inventor 谢捷明陈明晃
Owner FUJIAN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap